Difference between revisions of "Cytokeratin 19"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
'''Cytokeratin 19''', abbreviated '''CK19''', is a commonly available keratin. | '''Cytokeratin 19''', abbreviated '''CK19''', is a commonly available keratin [[immunostain]]. | ||
==Positive== | ==Positive== | ||
Revision as of 16:44, 9 May 2016
Cytokeratin 19, abbreviated CK19, is a commonly available keratin immunostain.
Positive
- Thyroid.[1]
- Gastrointestinal tract.[1]
- Pancreas.[1]
- Cholangiocarcinoma.
- Salivary gland - marks luminal cells.
- Adamantinoma.
- Yolk sac tumour.[2]
- Breast carcinoma - common (~91%).[3]
- Lung adenocarcinoma (~95%).[3]
Negative
See also
References
- ↑ 1.0 1.1 1.2 Jain, R.; Fischer, S.; Serra, S.; Chetty, R. (Jan 2010). "The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver.". Appl Immunohistochem Mol Morphol 18 (1): 9-15. doi:10.1097/PAI.0b013e3181ad36ea. PMID 19956064.
- ↑ Bremmer, F.; Ströbel, P.; Hubertus, H.; Strecker, J.; Gaisa, N.; Strauß, A.; Schweyer, S.; Radzun, H-J. et al. (2015). [www.diagnosticpathology.org/content/10/1/7Cached "CK19 is a sensitive marker for yolk sac tumours of the testis."]. Diagnostic Pathology 10 (7). doi:10.1186/s13000-015-0243-y. www.diagnosticpathology.org/content/10/1/7Cached.
- ↑ 3.0 3.1 Masai, K.; Nakagawa, K.; Yoshida, A.; Sakurai, H.; Watanabe, S.; Asamura, H.; Tsuta, K. (Dec 2014). "Cytokeratin 19 expression in primary thoracic tumors and lymph node metastases.". Lung Cancer 86 (3): 318-23. doi:10.1016/j.lungcan.2014.09.018. PMID 25453845.